2015/02 Synermore completed two hundred and sixty million Taiwan yuan ($8.25 million) cash capital increase
Synermore completed the cash capital increase in February 11, 2015. The A round fund-raising reached two hundred and sixty million Taiwan yuan (about US$8.25 million). The company has successfully raised more than about six trillion and eighty million Taiwan yuan (about US$22.68 million) of funds since its incorporation in 2013.
The raised fund will be used in clinical trials and enhance the new drug target identification, the remaining funds will be used for the company's operation and increase investment to the alliance, Beijing Synermore and Shenzhen Long Rui. The amount of capital increase is enough to complete two biotech similar drugs from preclinical to the initial clinical trial application (BLA).
Synermore Life Science (Beijing) Co. Ltd., mainly engaged in biological products, biotechnology and biological medicine; Shenzhen Long Rui Pharmaceutical Co. Ltd. is engaged in bio medicine preparation and GMP production, this investment will help Synermore to implement the global development strategy and provide innovative biological medicines to patients worldwide.